Share Price and Basic Stock Data
Last Updated: February 12, 2026, 10:09 pm
| PEG Ratio | 1.03 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Deccan Health Care Ltd operates in the Hospitals & Medical Services sector, with a current market capitalization of ₹33.4 Cr and a share price of ₹13.5. The company has shown a notable increase in its sales, which rose from ₹33.17 Cr in FY 2022 to ₹45.02 Cr in FY 2023, and is projected to reach ₹59.73 Cr in FY 2024 and ₹75.13 Cr in FY 2025. Quarterly sales figures also reflect a positive trend, with sales of ₹17.19 Cr reported in September 2023, a significant increase compared to ₹11.77 Cr in September 2022. This upward trajectory indicates a strong demand for Deccan Health’s services, contributing to a robust revenue growth strategy. However, the operating profit margin (OPM) has fluctuated, with the latest reported OPM at 7.01%, indicating a focus on improving operational efficiency. The company’s revenue from operations per share stood at ₹32.04 for FY 2025, further showcasing its revenue-generating capabilities.
Profitability and Efficiency Metrics
Deccan Health Care’s profitability has been characterized by significant variability, as highlighted by its net profit of ₹1.41 Cr for the latest fiscal year. The return on equity (ROE) is relatively low at 1.18%, highlighting potential concerns regarding the effective utilization of shareholder funds. However, the interest coverage ratio (ICR) stood at an impressive 42.55x, suggesting the company comfortably meets its interest obligations. The cash conversion cycle (CCC) has improved significantly, declining to 319.07 days, indicating enhanced efficiency in managing inventory and receivables. The net profit margin for FY 2025 was reported at 1.54%, which is lower than the industry average, suggesting that while revenue growth is promising, the company must streamline costs to enhance profitability. Overall, while Deccan Health has demonstrated some operational strengths, its profitability metrics indicate the need for continued focus on cost management and operational efficiency.
Balance Sheet Strength and Financial Ratios
Deccan Health Care’s balance sheet reflects a conservative financial structure, with total borrowings standing at ₹1.33 Cr against reserves of ₹84.21 Cr. This results in a low debt-to-equity ratio of 0.01, indicating minimal reliance on debt financing and a strong equity base. The book value per share is reported at ₹45.42 for FY 2025, suggesting a solid foundation of assets relative to liabilities. The current ratio is notably high at 6.77, which signifies excellent liquidity and the ability to cover short-term obligations. However, the company’s return on capital employed (ROCE) is low at 1.69%, raising concerns about the effectiveness of capital utilization for generating returns. Additionally, with a price-to-book value ratio of 0.37x, the stock appears undervalued compared to its book value, potentially providing an attractive entry point for investors. The balance sheet’s strength, combined with healthy liquidity ratios, positions the company favorably in a challenging market environment.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Deccan Health Care Ltd indicates a diverse ownership structure, with the public holding 76.21% of the shares, while promoters hold 18.42%. Institutional investors, including domestic institutional investors (DIIs), hold 5.37%, reflecting limited institutional interest. Over the past year, promoter holdings have seen a gradual decline from 22.21% in September 2022 to 18.42% in September 2025, which could signal a shift in confidence among promoters. The number of shareholders has increased significantly from 914 in September 2022 to 3,743 in September 2025, indicating growing interest and confidence among retail investors. This broadening of the investor base could enhance liquidity, but the declining promoter stake may raise questions about long-term commitment. Overall, while retail interest is robust, the changes in promoter holdings warrant attention from potential investors regarding future governance and strategic direction.
Outlook, Risks, and Final Insight
Looking ahead, Deccan Health Care Ltd faces both opportunities and challenges. The ongoing revenue growth, marked by a projected increase to ₹75.13 Cr in FY 2025, positions the company well to capitalize on the expanding healthcare market in India. However, the low profitability metrics, highlighted by a net profit margin of 1.54%, alongside fluctuating operational efficiency, present risks that could hinder sustained growth. The high liquidity ratios provide a cushion against short-term financial pressures, yet the low ROCE indicates potential inefficiencies in capital deployment. Moreover, the declining promoter shareholding may affect investor sentiment and long-term strategic alignment. For Deccan Health to navigate these challenges successfully, it must focus on improving operational efficiency, enhancing profitability, and maintaining investor confidence through transparent governance. The company’s performance in the upcoming quarters will be crucial in determining its trajectory in the competitive healthcare landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 48.5 Cr. | 145 | 187/120 | 117 | 2.42 % | 23.6 % | 20.7 % | 10.0 | |
| Global Longlife Hospital and Research Ltd | 13.4 Cr. | 12.8 | 33.0/11.6 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 9.80 Cr. | 9.47 | 20.5/7.08 | 18.7 | 0.00 % | 3.00 % | 0.81 % | 10.0 | |
| Fortis Malar Hospitals Ltd | 107 Cr. | 57.2 | 98.7/52.2 | 23.6 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.4 Cr. | 3.59 | 5.97/3.28 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,670.93 Cr | 709.80 | 83.37 | 92.86 | 0.34% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11.77 | 8.65 | 15.86 | 11.22 | 17.19 | 15.34 | 15.97 | 15.06 | 18.82 | 20.43 | 20.82 | 21.47 | 24.40 |
| Expenses | 10.96 | 8.83 | 15.07 | 10.40 | 16.16 | 14.10 | 15.31 | 14.19 | 17.70 | 19.83 | 20.19 | 20.75 | 22.69 |
| Operating Profit | 0.81 | -0.18 | 0.79 | 0.82 | 1.03 | 1.24 | 0.66 | 0.87 | 1.12 | 0.60 | 0.63 | 0.72 | 1.71 |
| OPM % | 6.88% | -2.08% | 4.98% | 7.31% | 5.99% | 8.08% | 4.13% | 5.78% | 5.95% | 2.94% | 3.03% | 3.35% | 7.01% |
| Other Income | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Interest | 0.03 | 0.04 | 0.03 | 0.02 | 0.00 | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 | 0.02 | 0.16 |
| Depreciation | 0.36 | 0.36 | 0.36 | 0.39 | 0.32 | 0.40 | 0.36 | 0.36 | 0.37 | 0.37 | 0.36 | 0.41 | 0.33 |
| Profit before tax | 0.42 | -0.57 | 0.41 | 0.42 | 0.71 | 0.82 | 0.29 | 0.49 | 0.72 | 0.21 | 0.25 | 0.30 | 1.22 |
| Tax % | 23.81% | -24.56% | 26.83% | 26.19% | 25.35% | 32.93% | 58.62% | 26.53% | 25.00% | 23.81% | 44.00% | 30.00% | 26.23% |
| Net Profit | 0.32 | -0.43 | 0.31 | 0.31 | 0.53 | 0.55 | 0.13 | 0.37 | 0.54 | 0.16 | 0.14 | 0.21 | 0.90 |
| EPS in Rs | 0.19 | -0.25 | 0.18 | 0.18 | 0.31 | 0.27 | 0.06 | 0.18 | 0.26 | 0.07 | 0.06 | 0.08 | 0.36 |
Last Updated: December 27, 2025, 8:32 am
Below is a detailed analysis of the quarterly data for Deccan Health Care Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 24.40 Cr.. The value appears strong and on an upward trend. It has increased from 21.47 Cr. (Jun 2025) to 24.40 Cr., marking an increase of 2.93 Cr..
- For Expenses, as of Sep 2025, the value is 22.69 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 20.75 Cr. (Jun 2025) to 22.69 Cr., marking an increase of 1.94 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.71 Cr.. The value appears strong and on an upward trend. It has increased from 0.72 Cr. (Jun 2025) to 1.71 Cr., marking an increase of 0.99 Cr..
- For OPM %, as of Sep 2025, the value is 7.01%. The value appears strong and on an upward trend. It has increased from 3.35% (Jun 2025) to 7.01%, marking an increase of 3.66%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.01 Cr. (Jun 2025) to 0.00 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Sep 2025, the value is 0.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Jun 2025) to 0.16 Cr., marking an increase of 0.14 Cr..
- For Depreciation, as of Sep 2025, the value is 0.33 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.41 Cr. (Jun 2025) to 0.33 Cr., marking a decrease of 0.08 Cr..
- For Profit before tax, as of Sep 2025, the value is 1.22 Cr.. The value appears strong and on an upward trend. It has increased from 0.30 Cr. (Jun 2025) to 1.22 Cr., marking an increase of 0.92 Cr..
- For Tax %, as of Sep 2025, the value is 26.23%. The value appears to be improving (decreasing) as expected. It has decreased from 30.00% (Jun 2025) to 26.23%, marking a decrease of 3.77%.
- For Net Profit, as of Sep 2025, the value is 0.90 Cr.. The value appears strong and on an upward trend. It has increased from 0.21 Cr. (Jun 2025) to 0.90 Cr., marking an increase of 0.69 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.36. The value appears strong and on an upward trend. It has increased from 0.08 (Jun 2025) to 0.36, marking an increase of 0.28.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:53 am
| Metric | Mar 2009 | Mar 2010 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29.26 | 39.52 | 16.16 | 29.34 | 37.83 | 44.25 | 42.24 | 33.78 | 33.17 | 45.02 | 59.73 | 75.13 | 87.12 |
| Expenses | 28.28 | 38.54 | 9.81 | 16.54 | 23.77 | 27.44 | 30.57 | 31.74 | 27.54 | 42.97 | 55.97 | 71.95 | 83.46 |
| Operating Profit | 0.98 | 0.98 | 6.35 | 12.80 | 14.06 | 16.81 | 11.67 | 2.04 | 5.63 | 2.05 | 3.76 | 3.18 | 3.66 |
| OPM % | 3.35% | 2.48% | 39.29% | 43.63% | 37.17% | 37.99% | 27.63% | 6.04% | 16.97% | 4.55% | 6.29% | 4.23% | 4.20% |
| Other Income | 0.09 | 0.09 | -0.17 | 0.05 | 2.07 | 0.08 | 0.06 | 0.06 | -3.46 | 0.02 | 0.01 | 0.01 | 0.01 |
| Interest | 0.01 | 0.10 | 1.48 | 2.14 | 1.50 | 1.04 | 0.18 | 0.11 | 0.15 | 0.11 | 0.06 | 0.07 | 0.22 |
| Depreciation | 0.02 | 0.22 | 1.15 | 1.19 | 1.28 | 1.29 | 1.42 | 1.47 | 1.47 | 1.43 | 1.47 | 1.45 | 1.47 |
| Profit before tax | 1.04 | 0.75 | 3.55 | 9.52 | 13.35 | 14.56 | 10.13 | 0.52 | 0.55 | 0.53 | 2.24 | 1.67 | 1.98 |
| Tax % | 17.31% | 30.67% | 0.28% | -0.21% | -0.15% | 0.62% | 0.39% | 25.00% | 40.00% | 26.42% | 32.59% | 28.14% | |
| Net Profit | 0.86 | 0.53 | 3.54 | 9.54 | 13.36 | 14.48 | 10.09 | 0.39 | 0.32 | 0.40 | 1.52 | 1.20 | 1.41 |
| EPS in Rs | 1.61 | 0.99 | 3.39 | 7.38 | 9.90 | 9.22 | 6.42 | 0.25 | 0.20 | 0.23 | 0.75 | 0.51 | 0.57 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2009-2010 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -38.37% | 169.49% | 40.04% | 8.38% | -30.32% | -96.13% | -17.95% | 25.00% | 280.00% | -21.05% |
| Change in YoY Net Profit Growth (%) | 0.00% | 207.86% | -129.45% | -31.66% | -38.70% | -65.82% | 78.19% | 42.95% | 255.00% | -301.05% |
Deccan Health Care Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2009-2010 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 31% |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -35% |
| 3 Years: | -20% |
| TTM: | -34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -14% |
| 3 Years: | -15% |
| 1 Year: | -33% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | 1% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 3:11 pm
Balance Sheet
Last Updated: December 4, 2025, 2:43 am
| Month | Mar 2009 | Mar 2010 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.33 | 5.33 | 10.43 | 12.93 | 13.50 | 15.71 | 15.71 | 15.71 | 15.71 | 17.04 | 20.38 | 23.43 | 24.75 |
| Reserves | 1.24 | 11.08 | -2.03 | 9.21 | 32.68 | 50.43 | 60.52 | 60.91 | 61.23 | 64.61 | 76.66 | 83.13 | 84.21 |
| Borrowings | 0.00 | 10.46 | 13.94 | 10.94 | 10.90 | 1.41 | 1.30 | 1.03 | 1.25 | 1.55 | 1.41 | 1.15 | 1.33 |
| Other Liabilities | 3.02 | 3.29 | 7.00 | 16.51 | 13.40 | 15.30 | 15.46 | 14.61 | 12.44 | 13.28 | 8.87 | 16.22 | 25.90 |
| Total Liabilities | 9.59 | 30.16 | 29.34 | 49.59 | 70.48 | 82.85 | 92.99 | 92.26 | 90.63 | 96.48 | 107.32 | 123.93 | 136.19 |
| Fixed Assets | 0.08 | 18.54 | 17.12 | 17.32 | 17.71 | 20.85 | 21.25 | 19.87 | 18.53 | 16.85 | 15.69 | 14.38 | 13.69 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 3.51 | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other Assets | 9.51 | 11.62 | 12.22 | 32.25 | 49.26 | 62.00 | 71.74 | 72.31 | 72.09 | 79.62 | 91.62 | 109.54 | 122.49 |
| Total Assets | 9.59 | 30.16 | 29.34 | 49.59 | 70.48 | 82.85 | 92.99 | 92.26 | 90.63 | 96.48 | 107.32 | 123.93 | 136.19 |
Below is a detailed analysis of the balance sheet data for Deccan Health Care Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 24.75 Cr.. The value appears strong and on an upward trend. It has increased from 23.43 Cr. (Mar 2025) to 24.75 Cr., marking an increase of 1.32 Cr..
- For Reserves, as of Sep 2025, the value is 84.21 Cr.. The value appears strong and on an upward trend. It has increased from 83.13 Cr. (Mar 2025) to 84.21 Cr., marking an increase of 1.08 Cr..
- For Borrowings, as of Sep 2025, the value is 1.33 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1.15 Cr. (Mar 2025) to 1.33 Cr., marking an increase of 0.18 Cr..
- For Other Liabilities, as of Sep 2025, the value is 25.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 16.22 Cr. (Mar 2025) to 25.90 Cr., marking an increase of 9.68 Cr..
- For Total Liabilities, as of Sep 2025, the value is 136.19 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 123.93 Cr. (Mar 2025) to 136.19 Cr., marking an increase of 12.26 Cr..
- For Fixed Assets, as of Sep 2025, the value is 13.69 Cr.. The value appears to be declining and may need further review. It has decreased from 14.38 Cr. (Mar 2025) to 13.69 Cr., marking a decrease of 0.69 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Other Assets, as of Sep 2025, the value is 122.49 Cr.. The value appears strong and on an upward trend. It has increased from 109.54 Cr. (Mar 2025) to 122.49 Cr., marking an increase of 12.95 Cr..
- For Total Assets, as of Sep 2025, the value is 136.19 Cr.. The value appears strong and on an upward trend. It has increased from 123.93 Cr. (Mar 2025) to 136.19 Cr., marking an increase of 12.26 Cr..
Notably, the Reserves (84.21 Cr.) exceed the Borrowings (1.33 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2009 | Mar 2010 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2009 | Mar 2010 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.98 | -9.48 | -7.59 | 1.86 | 3.16 | 15.40 | 10.37 | 1.01 | 4.38 | 0.50 | 2.35 | 2.03 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2009 | Mar 2010 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52.39 | 50.24 | 181.82 | 229.90 | 170.49 | 159.86 | 177.66 | 134.74 | 141.07 | 97.21 | 60.44 | 61.26 |
| Inventory Days | 48.33 | 34.08 | 269.62 | 432.36 | 596.97 | 773.64 | 825.88 | 890.81 | 1,182.75 | 683.64 | 445.05 | 326.33 |
| Days Payable | 42.96 | 31.06 | 264.36 | 447.94 | 173.22 | 185.88 | 153.84 | 112.09 | 146.00 | 123.28 | 41.39 | 68.52 |
| Cash Conversion Cycle | 57.76 | 53.25 | 187.08 | 214.32 | 594.24 | 747.62 | 849.70 | 913.46 | 1,177.82 | 657.58 | 464.10 | 319.07 |
| Working Capital Days | 55.51 | 51.72 | -155.17 | 193.82 | 240.82 | 321.94 | 421.77 | 545.99 | 603.01 | 502.26 | 477.19 | 423.69 |
| ROCE % | 5.08% | 42.08% | 32.94% | 25.03% | 14.21% | 0.81% | 5.62% | 0.79% | 2.53% | 1.69% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.54 | 0.80 | 0.22 | 0.21 | 0.25 |
| Diluted EPS (Rs.) | 0.45 | 0.80 | 0.22 | 0.21 | 0.25 |
| Cash EPS (Rs.) | 1.11 | 1.45 | 1.05 | 1.14 | 1.18 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 45.42 | 47.56 | 47.86 | 48.97 | 48.76 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 45.42 | 47.56 | 47.86 | 48.97 | 48.76 |
| Revenue From Operations / Share (Rs.) | 32.04 | 29.31 | 26.42 | 21.11 | 21.49 |
| PBDIT / Share (Rs.) | 1.35 | 1.85 | 1.21 | 3.54 | 1.33 |
| PBIT / Share (Rs.) | 0.72 | 1.13 | 0.36 | 2.61 | 0.39 |
| PBT / Share (Rs.) | 0.69 | 1.09 | 0.30 | 0.34 | 0.33 |
| Net Profit / Share (Rs.) | 0.49 | 0.73 | 0.21 | 0.20 | 0.24 |
| NP After MI And SOA / Share (Rs.) | 0.49 | 0.73 | 0.21 | 0.20 | 0.24 |
| PBDIT Margin (%) | 4.20 | 6.30 | 4.56 | 16.78 | 6.19 |
| PBIT Margin (%) | 2.27 | 3.84 | 1.39 | 12.34 | 1.85 |
| PBT Margin (%) | 2.17 | 3.70 | 1.14 | 1.63 | 1.53 |
| Net Profit Margin (%) | 1.54 | 2.49 | 0.80 | 0.97 | 1.15 |
| NP After MI And SOA Margin (%) | 1.54 | 2.49 | 0.80 | 0.97 | 1.15 |
| Return on Networth / Equity (%) | 1.08 | 1.54 | 0.44 | 0.41 | 0.50 |
| Return on Capital Employeed (%) | 1.56 | 2.28 | 0.73 | 5.10 | 0.78 |
| Return On Assets (%) | 0.92 | 1.38 | 0.37 | 0.35 | 0.42 |
| Long Term Debt / Equity (X) | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Total Debt / Equity (X) | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Asset Turnover Ratio (%) | 0.64 | 0.58 | 0.48 | 0.36 | 0.00 |
| Current Ratio (X) | 6.77 | 11.76 | 6.33 | 6.48 | 5.23 |
| Quick Ratio (X) | 4.05 | 5.67 | 2.43 | 2.05 | 1.69 |
| Inventory Turnover Ratio (X) | 1.70 | 0.65 | 0.68 | 0.08 | 0.00 |
| Interest Coverage Ratio (X) | 42.55 | 44.30 | 18.74 | 36.67 | 19.40 |
| Interest Coverage Ratio (Post Tax) (X) | 16.62 | 18.56 | 4.32 | 25.52 | 4.61 |
| Enterprise Value (Cr.) | 37.27 | 55.57 | 46.62 | 54.46 | 43.64 |
| EV / Net Operating Revenue (X) | 0.49 | 0.93 | 1.04 | 1.64 | 1.29 |
| EV / EBITDA (X) | 11.81 | 14.76 | 22.70 | 9.78 | 20.85 |
| MarketCap / Net Operating Revenue (X) | 0.52 | 0.94 | 1.04 | 1.69 | 1.37 |
| Price / BV (X) | 0.37 | 0.58 | 0.57 | 0.73 | 0.60 |
| Price / Net Operating Revenue (X) | 0.52 | 0.94 | 1.04 | 1.69 | 1.37 |
| EarningsYield | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Deccan Health Care Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.54. This value is below the healthy minimum of 5. It has decreased from 0.80 (Mar 24) to 0.54, marking a decrease of 0.26.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.45. This value is below the healthy minimum of 5. It has decreased from 0.80 (Mar 24) to 0.45, marking a decrease of 0.35.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.11. This value is below the healthy minimum of 3. It has decreased from 1.45 (Mar 24) to 1.11, marking a decrease of 0.34.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 45.42. It has decreased from 47.56 (Mar 24) to 45.42, marking a decrease of 2.14.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 45.42. It has decreased from 47.56 (Mar 24) to 45.42, marking a decrease of 2.14.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 32.04. It has increased from 29.31 (Mar 24) to 32.04, marking an increase of 2.73.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.35. This value is below the healthy minimum of 2. It has decreased from 1.85 (Mar 24) to 1.35, marking a decrease of 0.50.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.72. This value is within the healthy range. It has decreased from 1.13 (Mar 24) to 0.72, marking a decrease of 0.41.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.69. This value is within the healthy range. It has decreased from 1.09 (Mar 24) to 0.69, marking a decrease of 0.40.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.49. This value is below the healthy minimum of 2. It has decreased from 0.73 (Mar 24) to 0.49, marking a decrease of 0.24.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.49. This value is below the healthy minimum of 2. It has decreased from 0.73 (Mar 24) to 0.49, marking a decrease of 0.24.
- For PBDIT Margin (%), as of Mar 25, the value is 4.20. This value is below the healthy minimum of 10. It has decreased from 6.30 (Mar 24) to 4.20, marking a decrease of 2.10.
- For PBIT Margin (%), as of Mar 25, the value is 2.27. This value is below the healthy minimum of 10. It has decreased from 3.84 (Mar 24) to 2.27, marking a decrease of 1.57.
- For PBT Margin (%), as of Mar 25, the value is 2.17. This value is below the healthy minimum of 10. It has decreased from 3.70 (Mar 24) to 2.17, marking a decrease of 1.53.
- For Net Profit Margin (%), as of Mar 25, the value is 1.54. This value is below the healthy minimum of 5. It has decreased from 2.49 (Mar 24) to 1.54, marking a decrease of 0.95.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.54. This value is below the healthy minimum of 8. It has decreased from 2.49 (Mar 24) to 1.54, marking a decrease of 0.95.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 15. It has decreased from 1.54 (Mar 24) to 1.08, marking a decrease of 0.46.
- For Return on Capital Employeed (%), as of Mar 25, the value is 1.56. This value is below the healthy minimum of 10. It has decreased from 2.28 (Mar 24) to 1.56, marking a decrease of 0.72.
- For Return On Assets (%), as of Mar 25, the value is 0.92. This value is below the healthy minimum of 5. It has decreased from 1.38 (Mar 24) to 0.92, marking a decrease of 0.46.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.64. It has increased from 0.58 (Mar 24) to 0.64, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 6.77. This value exceeds the healthy maximum of 3. It has decreased from 11.76 (Mar 24) to 6.77, marking a decrease of 4.99.
- For Quick Ratio (X), as of Mar 25, the value is 4.05. This value exceeds the healthy maximum of 2. It has decreased from 5.67 (Mar 24) to 4.05, marking a decrease of 1.62.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.70. This value is below the healthy minimum of 4. It has increased from 0.65 (Mar 24) to 1.70, marking an increase of 1.05.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 42.55. This value is within the healthy range. It has decreased from 44.30 (Mar 24) to 42.55, marking a decrease of 1.75.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 16.62. This value is within the healthy range. It has decreased from 18.56 (Mar 24) to 16.62, marking a decrease of 1.94.
- For Enterprise Value (Cr.), as of Mar 25, the value is 37.27. It has decreased from 55.57 (Mar 24) to 37.27, marking a decrease of 18.30.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.49. This value is below the healthy minimum of 1. It has decreased from 0.93 (Mar 24) to 0.49, marking a decrease of 0.44.
- For EV / EBITDA (X), as of Mar 25, the value is 11.81. This value is within the healthy range. It has decreased from 14.76 (Mar 24) to 11.81, marking a decrease of 2.95.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 1. It has decreased from 0.94 (Mar 24) to 0.52, marking a decrease of 0.42.
- For Price / BV (X), as of Mar 25, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 0.58 (Mar 24) to 0.37, marking a decrease of 0.21.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 1. It has decreased from 0.94 (Mar 24) to 0.52, marking a decrease of 0.42.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Deccan Health Care Ltd:
- Net Profit Margin: 1.54%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.56% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.08% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 16.62
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 24 (Industry average Stock P/E: 83.37)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.54%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | 6-3-347/17/5/A/Back Position, Hyderabad Telangana 500082 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Minto Purshotam Gupta | Managing Director |
| Ms. Bhavika Sanghani | Director |
| Ms. Meenakshi Gupta | Director |
| Mr. Ravi Ramprasad | Director |
| Mr. Umanja Venkata Satya Siva Sriharikolla | Director |
| Ms. Samhitha Kandlakunta | Independent Director |
| Ms. Ruchi Khattar | Independent Director |
| Mr. Viraj Shaileshkumar Shah | Independent Director |
FAQ
What is the intrinsic value of Deccan Health Care Ltd?
Deccan Health Care Ltd's intrinsic value (as of 12 February 2026) is ₹12.54 which is 8.47% lower the current market price of ₹13.70, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹33.9 Cr. market cap, FY2025-2026 high/low of ₹25.6/13.0, reserves of ₹84.21 Cr, and liabilities of ₹136.19 Cr.
What is the Market Cap of Deccan Health Care Ltd?
The Market Cap of Deccan Health Care Ltd is 33.9 Cr..
What is the current Stock Price of Deccan Health Care Ltd as on 12 February 2026?
The current stock price of Deccan Health Care Ltd as on 12 February 2026 is ₹13.7.
What is the High / Low of Deccan Health Care Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Deccan Health Care Ltd stocks is ₹25.6/13.0.
What is the Stock P/E of Deccan Health Care Ltd?
The Stock P/E of Deccan Health Care Ltd is 24.0.
What is the Book Value of Deccan Health Care Ltd?
The Book Value of Deccan Health Care Ltd is 44.0.
What is the Dividend Yield of Deccan Health Care Ltd?
The Dividend Yield of Deccan Health Care Ltd is 0.00 %.
What is the ROCE of Deccan Health Care Ltd?
The ROCE of Deccan Health Care Ltd is 1.69 %.
What is the ROE of Deccan Health Care Ltd?
The ROE of Deccan Health Care Ltd is 1.18 %.
What is the Face Value of Deccan Health Care Ltd?
The Face Value of Deccan Health Care Ltd is 10.0.